STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany by Jansen, Klaus et al.
RESEARCH ARTICLE Open Access
STI in times of PrEP: high prevalence of
chlamydia, gonorrhea, and mycoplasma at
different anatomic sites in men who have
sex with men in Germany
Klaus Jansen1*† , Gyde Steffen1,2,3†, Anja Potthoff4, Ann-Kathrin Schuppe5, Daniel Beer6, Heiko Jessen7,
Stefan Scholten8, Petra Spornraft-Ragaller9, Viviane Bremer1, Carsten Tiemann5 and MSM Screening Study group
Abstract
Background: Men who have sex with men (MSM) are disproportionally affected by sexually transmitted infections
(STI). STI are often extragenital and asymptomatic. Both can delay diagnosis and treatment. Approval of HIV pre-
exposure prophylaxis (PrEP) might have influenced sexual behaviour and STI-prevalence of HIV- MSM. We estimated
STI-prevalence and risk factors amongst HIV- and HIV+ MSM in Germany to plan effective interventions.
Methods: We conducted a nationwide, cross-sectional study between February and July 2018. Thirteen MSM-
friendly STI-practices screened MSM for Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), Neisseria
gonorrhea (NG), and Trichomonas vaginalis (TV) using self-collected rectal and pharyngeal swabs, and urine samples.
APTIMA™ STI-assays (Hologic™ Inc., San Diego, USA) were used for diagnostics, and samples were not pooled. We
collected information on socio-demographics, HIV-status, clinical symptoms, sexual behaviour within the last 6
months, and PrEP use. We combined HIV status and PrEP use for defining risk groups, and used directed acyclic
graphs and multivariable logistic regression to identify risk factors for STI.
Results: Two thousand three hundred three MSM were included: 50.5% HIV+, median age 39 [18–79] years. Median
number of male sex partners within the last 6 months was five. Sex without condom was reported by 73.6%, use of
party drugs by 44.6%. 80.3% had a STI history, 32.2% of STI+ MSM reported STI-related symptoms. 27.6% of HIV-
MSM used PrEP.
Overall STI-prevalence was 30.1, 25.0% in HIV−/PrEP- MSM (CT:7.2%; MG:14.2%; NG:7.4%; TV:0%), 40.3% in HIV−/PrEP+
MSM (CT:13.8%; MG:19.4%; NG:14.8%; TV:0.4%), and 30.8% in HIV+ MSM (CT:10.1%; MG:18.4%; NG:8.6%; TV:0.1%).
Being HIV+ (OR 1.7, 95%-CI 1.3–2.2), using PrEP (OR 2.0, 95%-CI 1.5–2.7), having > 5 sex partners (OR:1.65; 95%-CI:
1.32–2.01.9), having condomless sex (OR:2.11.9; 95%-CI:1.65–2.86), and using party drugs (OR:1.65; 95%-CI:1.32–2.0)
were independent risk factors for being tested positive for at least one STI.
Conclusions: We found a high STI-prevalence in MSM in Germany, especially in PrEP users, frequently being
asymptomatic. As a relevant proportion of PrEP users will not use a condom, counselling and comprehensive STI
screening is essential and should be low threshold and preferably free of cost. Counselling of PrEP users should also
address use of party drugs.
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Background
Men who have sex with men (MSM) are dispropor-
tionally affected by sexually transmitted infections
(STI), such as Chlamydia trachomatis (CT), Neisseria
gonorrhoeae (NG), or syphilis [1–7]. STI are often
asymptomatic, and therefore remaining frequently un-
detected and untreated [8]. This may lead to severe
sequelae, and serve as ongoing transmission reservoir.
Extragenital STI in MSM are frequent [8–12] and can
contribute substantially to the further spread if not
diagnosed and treated. In previous studies, HIV-
positive (HIV+) MSM often showed higher preva-
lences of STI than HIV-negative (HIV-) MSM [13,
14]. As reasons for higher STI prevalence in MSM in
general, higher number of sexual partners as well as
higher frequencies of sexual practices with higher risk
for acquiring STI are discussed [3, 6, 7, 14]. In
Germany, medical guidelines recommend risk adapted
STI testing for MSM [15], but costs are not covered
by German health insurance if patients do not show
STI-related symptoms or if there is no clear report of
a substantial risk of infection. In these cases, patients
have to bear costs for STI testing privately or physi-
cians risk claim for damages by balancing accounts
with insurance companies for testing asymptomatic
patients. Therefore the scope of asymptomatic, un-
detected and potentially transmissible STI in MSM in
Germany remains still unknown and may be high.
In 2016 pre-exposure prophylaxis (PrEP) against HIV in-
fection was approved in Germany. For PrEP, tenofovir diso-
proxil fumarate and emtricitabine is taken by patients
preferably as daily oral medication, showing high effectivity
against HIV infection [16–21]. MSM with increased sexual
risk behavior and/or recent STI are eligible for PrEP ac-
cording to WHO guidelines as well as guidelines of the
German-Austrian medical AIDS society [22, 23]. The latter
recommend syphilis testing for PrEP users every 3 months,
and testing for CT and NG every three to 6 months. PrEP
users in Germany had to bear the expenses for PrEP and all
corresponding tests (HIV, STI, creatinine) privately until re-
cently. Since September 2016, several generic medicaments
for PrEP were available and reduced costs distinctly (ca. 50
€/month), leading to a broader implementation of PrEP in
Germany. Since September 1st 2019, German compulsory
health insurance covers the costs of PrEP and related test-
ing of necessary clinical parameters and STI (ca. 90% of the
population). The frequency of testing as well as its extent
will be individually defined by the treating physician ac-
cording to risk behavior and/or symptoms and will be cov-
ered by the health insurance for the evaluation phase of
PrEP in Germany [24].
Despite the license of PrEP includes the recommenda-
tion of regular condom use for PrEP users, it is probable
that one of the main reasons for taking PrEP is that
persons can effectively reduce their risk for acquiring a
HIV infection without using condoms. Since PrEP was in-
troduced it is under debate to what extent a concomitant
reduction of condom use and a potential increase of more
risky sexual behavior will lead to an increase of other STI
[25–30]. In contrast, recommended regular and small me-
shed STI testing is discussed as an argument against an in-
crease of STI due to PrEP, as this could lead to more
efficient diagnosis and treatment of newly acquired STI as
well as of so far undiagnosed reservoirs in populations
with high risk such as sexually highly active MSM [31, 32].
Subsequently, a reduction of STI prevalence could result
in the medium and long term.
As the national approval of PrEP in 2016 may have an in-
fluence on sexual behavior and STI prevalence in MSM in
general, the need of systematic data on STI prevalence in
MSM is urgent to estimate their STI risk, to provide reliable
data to define appropriate testing algorithms for MSM using
PrEP or not, and to plan effective preventional measures for
PrEP using MSM and all other MSM at risk for STI.
With the “MSM Screening Study” we aimed estimating
the current prevalence of CT, NG, Mycoplasma genitalium
(MG) and Trichomonas vaginalis (TV) as well as relevant
risk factors among the general MSM population (HIV+ and
HIV-) in Germany and to compare STI prevalences system-
atically by HIV status, PrEP use and localization.
Methods
Study type
Between February and August 2018, we conducted a na-
tionwide cross-sectional multicentre study to estimate the
prevalence of CT, MG, NG and TV in MSM in nine large
cities across Germany (Aachen, Berlin, Bochum, Cologne,
Dortmund, Dresden, Munich, Nuremberg, and Stuttgart).
Setting, study population
For the study we recruited a convenience sample of
MSM-friendly practices with infectiological focus that
were frequently visited by HIV-positive and HIV-
negative MSM, due to their profile also serving as gen-
eral practitioners for MSM. Of 30 requested sites, 13
participated in the study (Fig. 1).
Within the testing period all MSM attending the testing
site were invited to participate in the study, independent
from the reason of their visit or any symptoms. The partici-
pants did not receive any incentive for taking part in the
study.
Inclusion criteria
Inclusion criteria were: age >=18 years, no former partici-
pation in the MSM Screening Study, known HIV-status
(HIV test result within the last 12months), no antibiotic
STI therapy within the last 4 weeks and informed
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consent to take a pharyngeal and rectal swab and to
provide a urine sample to be tested for CT, NG, MG
and TV.
Data and samples collected
Study questionnaire
The study participants filled in a standardised self-
administered questionnaire that was designed specific-
ally for the study (Additional file 1). It consisted of
20 questions gathering information on sociodemo-
graphics, sexual behaviour and use of drugs (alcohol,
Cannabis, Heroine, Poppers, Cocaine/Speed, Ecstasy,
Viagra/Cialis, Speed, GLB/GHB, Crystal Meth, Bath
salts/ Spice) in the last 6 months, STI-related symp-
toms in the last 4 weeks, STI history, HIV status
(plus where applicable information on HIV therapy
and outcome) and current use of PrEP. The HIV-
status was also obtained from the testing site.
Fig. 1 Geographical distribution of study sites of the MSM Screening Study (map authors' own)
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Sample collection and diagnostic tests
Biological samples were obtained using rectal and
pharyngeal swabs, and urine samples. Samples were self-
collected (with Aptima™ Multitest Swab Specimen Col-
lection Kit and Aptima™ Urine Specimen Collection Kit),
after instruction by the medical staff of the testing site
and using a photograph -based demonstration material
especially developed for the MSM Screening Study.
The samples were not pooled and tested by
transcription-mediated amplification with the Hologic™
(Hologic Inc., San Diego, USA) APTIMA Combo 2™
Assay for CT and NG; the APTIMA™ Mycoplasma geni-
talium Assay for MG and the APTIMA™ Trichomonas
vaginalis Assay for TV, using the Hologic™ Panther
System.
Statistical analysis
With an estimated STI prevalence of 6% among HIV-
negative and 12% among HIV-positive MSM, a power of
80% and a precision of 2 to 3%, a study population size
of 1200 HIV- and 980 HIV+ participants was needed for
sufficient prevalence estimations related to HIV-status.
To ensure sufficient statistical power prevalence estima-
tions for both, HIV- and HIV+ MSM, HIV+ MSM were
oversampled compared to their proportion of the overall
MSM population in Germany. With an estimated re-
sponse rate of 70%, 1700 HIV-negative and 1400 HIV-
positive MSM had to be invited for participation in the
study.
We described the study population calculating fre-
quencies and proportions for dichotomous and categor-
ical variables and the median for continuous variables
(age). We calculated the overall prevalence for CT, NG,
MG and TV including 95% confidence intervals (95%-
CI), and tested bivariable correlations between sociode-
mographic/behavioural factors and STI prevalence using
chi-squared test and Wilcoxon-Mann-Whitney test as
appropriate.
We stratified for HIV-status for prevalence calcula-
tions. Additionally, we combined HIV and PrEP use to
define meaningful risk profiles. The three different risk
groups were HIV positive MSM (HIV+), HIV-negative
non-PrEP users (HIV−/PreP-) and HIV-negative PrEP
users (HIV−/PrEP+).
As basis for the multivariable analyses, we used di-
rected acyclic graphs (DAGs) [33] to explore the poten-
tial causal relationships between the risk groups, sexual
behaviour and being tested positive for at least one STI
considering several co-variates. Moreover we identified
minimally sufficient adjustment sets to minimize con-
founding. As sexual behaviour was shown to be on the
causal path between PrEP use/ HIV status and STI sta-
tus, we developed two separate multivariable regression
models. First, we investigated statistical associations
between the three risk groups and the outcome “tested
positive for at least one STI”, additionally sub-analysing
the influence of HIV status (excluding PrEP users) and
PrEP use (excluding HIV-positive MSM) on tested posi-
tive for at least one STI separately. In a second step, we
estimated associations between sexual behaviour and the
same outcome. Differences in sexual behaviour between
the risk groups were analysed descriptively.
For multivariable analyses we used manually stepwise
forward selected logistic regression calculating odds ra-
tios (OR). We tested all eligible factors bivariable associ-
ated with the outcome at p < 0.2. The overall
significance level was set at p < 0.05.
All analyses were performed using STATA V.14 soft-
ware package (StataCorp LP, College Station, Texas,
USA).
Data protection
A unique identifier (barcode) was used to allocate sam-
ples and questionnaires to the participants. The testing
sites received the test results and could link them via
barcode to their patients. At the laboratory, the barcode
was removed from the datasets after linking of the la-
boratory data with the data of the questionnaire. The
Robert Koch Institute received a completely anonymised
dataset for analysis.
Test results were communicated from the laboratory
to the testing sites within 24 h. All participants tested
positive for any of the measured STI were informed and
consulted by their attending physician and could receive
treatment by their testing site based on the national STI
treatment guideline.
Results
Demographic characteristics and sexual behaviour of the
study population
Between 20/2/2018 and 2/7/2018, 2321 MSM partici-
pated in the study, between 32 and 312 MSM by each
site. Complete test results for all four pathogens and in-
formation on HIV-status were available for 2303 of
them, constituting the final study population. 50.5%
(1164/2303) of all participants were HIV+. 91.4% of
them were diagnosed with HIV longer than 12months
before study entry, 98.4% were on antiviral treatment
and 84.2% reported a viral load below the detection
limit. Of the HIV- participants, 27.6% (283/1024) re-
ported current PrEP use (HIV−/PrEP+), 72.4% (741/
1024) did currently not taking PrEP (HIV−/PrEP-).
34.2% of all participating MSM were between 30 and
40 years old (Table 1), HIV+ MSM were older than HIV
−/PrEP- and HIV−/PrEP+ (median 44 [20–79] vs. 34
[18–73] and 35 [20–66]). Participants not being born in
Germany (25.9%) came from various countries all over
the world, mostly from Brazil (7.4% of foreign born
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MSM), United States of America (6.4%), Italy (6.0%),
and Poland (5.5%). HIV−/PrEP+ were more often born
abroad (37.2%) than HIV−/PrEP- (30.9%) and HIV+
(19.2%). HIV−/PrEP+ and HIV−/PrEP- had more often a
university-entrance diploma (80.2 and 79.5%) than HIV+
(54.4%).
Most participating MSM reported to be single (44.8%)
or to live in an open relationship with an agreement for
sex with others (32.6%). Most stated to have met their
sex partners on the internet (77.6%), in bars (36.8%) or
in saunas (28.4%). The proportion of singles and MSM
in open relationships was higher in HIV−/PrEP+ (96.8%)
than in HIV−/PrEP- and HIV+ MSM (82.9 and 76.7%,
respectively). 44.9% of all participants reported more
than five male sex partners during the last 6 months, the
proportion was higher in HIV−/PrEP+ (79.8%) than in
HIV−/PrEP- (46.1%) and HIV+ (36.4%). Condomless
anal intercourse (CAI, insertive and/or receptive) was re-
ported by 73.2%, and more frequently from participating
MSM reporting more than five sex partners (84.6%) than
from MSM reporting one to four sex partners (66.5%),
and more frequently from HIV−/PrEP+ (91.8%) than
from HIV−/PrEP- (67.3%) and HIV+ MSM (73.1%).
The most frequently used risk reduction strategies to
avoid HIV-infection when not using condoms were to
ask the partner for his HIV-status (40%), only to have
sex with HIV+ partners if they have an undetectable
viral load (26.2%), only to have sex without a condom in
a monogamous relationship (20.3%) and to use PrEP
(15.6%).
Table 1 Sociodemographic, behavioral and clinical characteristics of the study population, by HIV/PrEP-status
Nb ALL HIV+ HIV−/PrEP- HIV−/PrEP+
2303a 1164 745 283
Demographicsc
Age (median [range]; n = 2287) 39 [18–79] 44 [20–79] 34 [18–73] 35 [20–66]
Born in Germany (%; n = 2168) 74.5 80.8 69.1 62.8
University-entrance diploma (%; n = 2157) 66.2 54.4 79.5 80.2
Sexual behavior in the last 6 months
Number of sex partners (median [range]; n = 1935) 5 [0–820] 4 [0–820] 5 [0–120] 11 [1–240]
Sex without condom (%, n = 2148) 73.6 73.1 67.3 91.8
Condomless anal intercourse (insertive; %; n = 2076) 55.7 56.8 51.5 78.4
Condomless anal intercourse (receptive; %; n = 2077) 59.2 63.7 46.6 73.8
Condomless oral intercourse (insertive; %; n = 2077) 87.2 83.9 89.6 94.0
Condomless oral intercourse (receptive; %; n = 2078) 81.2 76.1 85.9 88.7
Rimming (active; %; n = 2075) 54.9 49.3 56.0 73.1
Rimming (passive; %; n = 2076) 58.1 52.4 62.1 77.0
Fisting (active; %; n = 2072) 15.5 16.0 11.8 23.0
Fisting (passive; %; n = 2072) 9.6 11.7 5.9 11.7
Use of drugs (%; n = 2123) 67.7 64.3 66.6 84.2
Use of party drugs (%; n = 2123) 44.6 42.9 39.6 64.4
Paid for sex (%; n = 1814) 3.5 3.7 3.4 2.7
Being paid for sex (%; n = 1791) 2.8 2.9 2.9 2.6
STI history
STI in medical history (%, n = 1908) 80.3 96.6 59.4 81.1
Chlamydia trachomatis (%, n = 2148) 39.8 42.6 30.9 52.1
Hepatitis B (%, n = 2144) 11.0 16.7 4.0 5.7
Hepatitis C (%, n = 2145) 8.6 15.0 1.2 1.8
Mycoplasma genitalium (%, n = 2139) 6.9 5.8 5.8 14.2
Neisseria gonorrhoeae (%, n = 2188) 46.3 48.6 37.9 58.9
Treponema pallidum (%, n = 2155) 40.9 55.4 20.8 33.7
Report of STI-related clinical symptoms in the last four weeks (%; n=;642) 32.2 29.1 37.7 33.0
aThe total number of study participants also includes HIV-negative MSM with no data given on their PrEP use
bThe N represents the number of participants in each group
cThe n represent the number of participants answering the question
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The mainly reported substances used in the context of
sexual encounters within the last 6 months were alcohol
(80.6%), Poppers (53.9%), Viagra/Cialis (33.9%), and
Cannabis (31.9%). 43.5% of all participants reported to
use so called party drugs (defined as Cocaine, Crystal
Meth, Ecstasy, GBL/GHB, Mephedron/Spice, Poppers
and Speed) in the context of sexual encounters within
the last 6 months; the use of party drugs was higher in
HIV−/PrEP+ (64.4%) than in HIV−/PrEP- (39.6%) and
HIV+ MSM (42.9%). The detailed population character-
istics are summarized in Table 1.
HIV- participants were significantly younger than
HIV+ MSM (median 35 IQR [30–43] vs. 44 [35–52],
p < 0.01) and less likely to be born in Germany (67.2%
vs. 80.8%, p < 0.01), but they were more likely to have
acquired university-entrance diploma (74.6% vs. 54.4%,
p < 0.01). The median number of male sex partners was
significantly higher in HIV- MSM than in HIV+ (6 [3–
15] vs. 4 [1–10], p < 0.01). There was no difference in
having sex without using condoms in the last 6 months
(73.1% vs. 73.4%, p = 0.88). The proportion of reported
insertive condomless anal intercourse (CAI) did not dif-
fer between HIV- and HIV+ MSM (58.4% vs. 56.8%, p =
0.460). HIV- participants reported more insertive con-
domless oral intercourse (COI) (90.0% vs. 83.9%, p <
0.05) and receptive COI (86.0% vs. 76.1%, p < 0.05), but
less receptive CAI (52.8% vs. 63.7%, p < 0.05). The use of
party drugs did not differ between both groups (44.2 vs.
42.9%, p = 0.56). The proportion of participants with a
STI history was significantly lower in HIV- participants
(64.0 vs. 96.6%, p < 0.01). The proportion of clinical
symptoms among positive STI-tested participants did
not differ between both (35.4 vs. 29.1%, p = 0.08).
Regarding sociodemographics HIV−/PrEP- and HIV
−/PrEP+ did not significantly differ. The differences be-
tween HIV+ and HIV- participants are described above.
HIV−/PrEP+ reported the highest number of male sex
partners (median 11 IQR [6–25]) and the highest pro-
portion of sex without using condoms (91.8%), including
insertive and receptive CAI (78.4, 73.8%) and COI (94.0,
88.7%). Also they reported to more frequently use party
drugs (64.4%). The report of symptoms in positive tested
participants was highest in HIV−/PrEP- (37.7%),
followed by HIV−/PrEP+ (33.0%) and HIV+ (29.1%).
The proportion of a previous STI was highest in HIV+
MSM (96.6%), followed by HIV−/PrEP+ (81.1%) and
lowest in HIV−/PrEP- (59.4%).
Prevalence of CT, MG, NG, and TV
All together 30.1% (693) of all participants were tested
positive for at least one of the tested STI (for specific
prevalences, see Table 2), MG was the most prevalent
pathogen (17.0%), TV was diagnosed only in 2 partici-
pants (Table 2).
16.9% (117) of participants were tested positive for
more than one pathogen, of those 35.9% [34] for CT/
MG, 28.2% [33] for CT/NG, 23.9% [28] for NG/MG, and
12.0% [14] for CT/MG/NG.
50.6% (351) of all diagnosed STI were solely mani-
fested rectal, 11.1% (77) pharyngeal, 13.7% (95) urethral,
and 24.5% (170) of all infections were manifested in
more than one anatomical location. While for CT and
MG the prevalence was lowest for pharyngeal infections,
for NG the prevalence for pharyngeal infections was
higher than for urogenital infections (Table 2). Rectal
MG exhibited the highest prevalence (11.5%) of all diag-
nosed STI.
Clinical symptoms of STI-positive participants
About a third of all participants reported STI-related
clinical symptoms in the last 4 weeks, this differed
slightly between risk groups (Table 1). The proportion
of STI-positive diagnosed participants that reported clin-
ical symptoms was 32.1% overall, and highest in partici-
pants with urogenital only infections (37.0%), followed
by rectal only (28.3%) and oral only infections (24.0%).
The proportion of reported symptoms in participants
with multiple site infections was 41.1%. Stratified by
pathogen, 29.3% of all only CT-positive participants,
40.9% of all only NG-positive participants, and 29.3% of
all only MG-positive participants reported clinical
symptoms.
Impact of HIV status and PrEP use on STI prevalence
HIV status
The overall STI prevalence did not significantly differ
between HIV- and HIV+ participants (30.8% vs. 29.4%,
p = 0.48), as did not the single prevalences of CT (10.1%
vs. 9.6%, p = 0.65), NG (8.6% vs. 9.2%, p = 0.60), and MG
(18.4% vs. 15.5%, p = 0.07). The overall STI prevalence
did not significantly differ between HIV+ participants
having a HIV viral load below the detection limit (29.2%
vs. 33.3%, p = 0.46) or above.
Risk groups HIV+ MSM, HIV−/PrEP- MSM, HIV−/PrEP+ MSM
The overall STI prevalence was highest in HIV−/PrEP+
MSM (40.3%), followed by HIV+ (30.8%) and HIV
−/PrEP- (25.0%). The single prevalences for the different
pathogens and anatomical sites showed a similar pattern
(see Figs. 2 and 3). The prevalence for all tested patho-
gens and locations was highest in HIV−/PrEP+. While
the prevalence for pharyngeal and urogenital infections
was similar in non-PrEP users and HIV+ MSM (p <
0.05), the prevalence for rectal infections was higher in
HIV+ MSM.
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Independent risk factors for STI
The final multivariable regression model on the effect of
the three risk groups on being tested positive for at least
one STI included age, city of testing and country of
birth. Being HIV+ (OR 1.7, 95%-CI 1.3–2.2) or using
PrEP (OR 2.0, 95%-CI 1.5–2.7) were independent risk
factors, also partly younger age groups (Table 3).
The regression model on the effect of HIV in MSM
not using PrEP (HIV+ MSM vs. HIV−/PrEP- MSM) on
being tested positive for at least one STI included age,
city of testing and country of birth and showed HIV+ as
independent risk factor (OR 1.8, 95%-CI 1.4–2.3; Add-
itional file 2: Table S1). The likewise model on the effect
of PrEP use in HIV- MSM included the same variables
and showed PrEP use as independent risk factor (OR
2.0, 95%-CI 1.5–2.7; Additional file 1: Table S2).
The regression model on the influence of sexual be-
havior on being tested positive for at least one STI in-
cluded the variables age group, city of testing, number of
male sexual partners, sex without condom, and the use
of party drugs. Independent risk factors were having
more than five male sex partners within the last 6 month
(OR 1.6, 95%-CI 1.2–2.0), having sex without using a
condom within the last 6 month (OR 2.1, 95%-CI 1.6–
2.8) and the use of party drugs within the last 6 months
(OR 1.6, 95%-CI 1.3–2.0; Table 4). Younger age was an
independent risk factor, partly significant, partly nearly
reaching level of significance (Table 4).
Discussion
The MSM Screening Study enabled us to picture the
STI epidemiology in an extensive sample of MSM in
Germany during a period of large-scale PrEP implemen-
tation. Overall, nearly one of three MSM was diagnosed
with at least one of the tested STI, and the prevalence
was significantly higher in PrEP users.
STI prevalences
With 17.0%, the prevalence of MG nearly doubled that
of CT or NG. Currently, there is only limited data
Table 2 Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis, by
pathogen and anatomical location
N = 2203 Any STI CT NG MG TV Multiple pathogens
n % 95%-CI n % 95%-CI n % 95%-CI n % 95%-CI n % 95%-CI n % 95%-CI
Any site 693 30.1 28.2–32.0 227 9.9 8.7–11.1 205 8.9 7.8–10.1 391 17 15.5–18.6 2 0.1 0.01–0.3 117 5.1 4.2–6.0
Pharynx 192 8.3 7.2–9.5 26 1.1 0.7–1.6 110 4.8 3.9–5.7 66 2.9 0.2–0.3 0 0 0 48 2.1 1.5–2.7
Rectum 503 21.8 20.2–23.6 178 7.7 6.7–8.9 133 5.8 4.8–6.8 265 11.5 10.2–12.9 2 0.1 0.01–0.3 102 4.4 3.6–5.3
Urine 192 8.3 7.2–9.5 45 2.0 1.4–2.6 32 1.4 0.9–1.9 124 5.4 4.5–6.4 0 0 0 48 2.1 1.5–2.7
Multiple sites 170 7.4 6.3–8.5 63 2.7 2.1–3.5 91 3.9 3.2–4.8 99 4.3 3.5–5.2 0 0 0 72 3.1 2.4–3.9
Fig. 2 Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium, by HIV/PrEP-status (n = 2303)
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available on MG in MSM. A meta-analysis found much
lower prevalence estimates for MSM of 3.2% in five
community-based studies from Australia and Central
America and 3.7% in four clinic-based studies from Eur-
ope and the US [35]. Other studies found MG preva-
lences between 2.0 and 13.4%, and differed in the
number of tested sites, clinical status, and reported sex-
ual behavior [36–42].
In comparison to results of the hitherto existing stud-
ies, the MSM Screening Study conducted in 2018 found
one of the highest MG prevalences in MSM reported, in
particular for pharyngeal MG infections, which are re-
ported to be rare in previous studies [34, 39, 40, 43], but
also for anorectal infections. The high MG prevalence in
our study is of special interest. We deliberately recruited
at MSM friendly practices with a general practitioner
profile and not only serving as sexual health centers.
Therefore, we could recruit a nationwide large sample of
a more general MSM population and not only MSM
with distinct high sexual risk behavior. As a result, we
expected the STI prevalences in our study to be lower
than those found in studies conducted in specialized STI
testing facilities. Possible reasons for the lower preva-
lences in previous studies could be that testing was only
performed in one or two localizations, study populations
had lower risk profiles, or general epidemiological differ-
ences by person, place and time. Whether the increasing
MG prevalence in more recent studies is a real trend or
due to demographic, behavioural or clinical differences
between the study populations remains unclear.
Fig. 3 Prevalence of any STI, by anatomical location and HIV/PrEP-Status (n = 2303)
Table 3 Independent risk factors for STI-acquisition regarding
risk groups, bivariable and multivariable logistic regression (n =
2145)
Bivariable analysis Multivariable analysis*
OR 95%-CI p OR 95%-CI p
Risk group (ref. HIV−/PrEP-)
HIV+ 1.33 1.08–1.64 0.01 1.7 1.34–2.16 0.00
HIV−/PrEP+ 2.03 1.51–2.70 0.00 1.98 1.46–2.66 0.00
Demographics
Age groups (ref. 40–49 yrs)
18–24 yrs 0.82 0.51–1.31 0.40 1.08 0.64–1.79 0.78
25–29 yrs 1.46 1.08–1.96 0.01 1.48 1.08–2.04 0.02
30–39 yrs 1.26 1.00–1.59 0.05 1.16 0.90–1.48 0.24
50–59 yrs 0.69 0.51–0.91 0.01 0.67 0.50–0.91 0.01
> 59 yrs 0.45 0.25–0.81 0.01 0.5 0.28–0.91 0.02
City of testing (ref. Cologne)
Aachen 0.48 0.36–0.91 0.02 0.68 0.42–1.09 0.11
Berlin 1.2 0.88–1.63 0.26 1.22 0.87–1.70 0.24
Bochum 0.58 0.39–0.85 0 0.66 0.44–1.0 0.05
Dortmund 0.77 0.46–1.28 0.31 0.91 0.54–1.54 0.74
Dresden 1.00 0.61–1.62 0.99 1.07 0.65–1.77 0.79
Munich 1.19 0.82–1.73 0.94 1.15 0.78–1.71 0.48
Nurnberg 1.56 0.73–3.32 0.25 1.53 0.69–3.40 0.29
Stuttgart 0.99 0.66–1.49 0.96 1.03 0.67–1.59 0.88
Country of birth (ref. Germany)
Other country 1.24 1.01–1.51 0.04 1.06 0.85–1.32 0.60
* p < 0.01 for overall multivariable logistic regression model
Jansen et al. BMC Infectious Diseases          (2020) 20:110 Page 8 of 14
Moreover, test sensitivity may play a role, as RNA tar-
geting Aptima TMA technology usually shows higher
sensitivity for STI than DNA targeting PCR based assays
used in some previous studies.
The overall prevalence of CT (10.1%) and NG (8.6%)
in our study were lower than for MG, but still high, and
comparable to other studies among MSM, especially in
Western countries. Globally, prevalences varied between
1 and 24% for CT, and 0 and 54% for NG [8, 11, 44–55],
depending on the type of the recruiting institution, clin-
ical symptoms, HIV status and sexual behaviour of the
participants. Extragenital as well as asymptomatic infec-
tions were reported to be common.
For NG, a distinct higher proportion of the overall
prevalence was diagnosed pharyngeal. Despite a higher
rate of spontaneous clearance and a shorter persistence
of NG in the throat than in other localizations, this
higher proportion of pharyngeal NG is of special con-
cern, as the pharynx is an important reservoir for the de-
velopment of antimicrobial resistance (AMR) of NG
[56]. To eliminate the often asymptomatic pharyngeal
NG as a transmission reservoir as well as to reduce the
development of AMR, antiseptic mouthwash as a non-
antibiotic preventive intervention has been suggested
[57–59], but efficacy has yet to be established.
The high proportion of extragenital and asymptomatic
infections in our study draws the attention to their high
impact for an ongoing transmission of STI in MSM
population by not diagnosing and treating them effect-
ively [12, 39, 40]. The WHO recommends to have re-
spective screening offers for MSM if the prevalence of
asymptomatic pharyngeal and rectal infections exceeds 1
to 2% [60].
By only testing the participants for urogenital STI in
our study, we would have only found 27.7% of all diag-
nosed infections. If no general screening offers for MSM
would be available, only symptomatic MSM would at-
tend the practices for STI testing. To assess the impact
of clinical symptoms for an effective STI care in MSM,
we used information from self-reported STI-related
symptoms. By exclusively testing MSM reporting STI-
related symptoms, only 31.0% of all diagnosed STI
would have been identified. The proportion of missed
MG diagnoses would have been the highest in this
context.
Given the high overall prevalences of CT, MG and NG
in our study and the high proportions of extragenital
and asymptomatic infections, the results strongly sup-
port broadly implemented STI-screening offers for MSM
with special emphasis of screening at all three
localizations.
We found only two infections with TV in the study
population, which corresponds with low prevalence also
found in other comparable studies on TV in MSM. A
low prevalence in MSM may be due to a general higher
persistence of this pathogen in the female urogenital
tract [61–63]. On basis of the study results, the inclusion
of TV in a regular STI testing scheme for MSM is not
recommend.
Although syphilis is an important STI among MSM [2,
13, 64], the need for drawing additional blood might
have led to a decrease in participation and have reduced
the power of the results. Therefore, we did not test for
syphilis in our study.
Risk factors for STI
A substantial number of PrEP users participated in the
MSM Screening Study. The prevalence for each of the
tested STI and at each localisation was highest among
PrEP using HIV- MSM. PrEP users also reported distinct
higher sexual risk behaviour. Additionally, PrEP use was
an independent risk factor for diagnosis of STI in the
multivariable model.
Table 4 Independent risk factors for STI-acquisition regarding
sexual behaviour, bivariable and multivariable logistic regression
(n = 1864)
Bivariable analysis Multivariable analysis*
OR 95%-CI p OR 95%-CI p
Demographics
Age in groups (ref. 40–49 yrs)
18–24 yrs 0.82 0.51–1.31 0.40 1.10 0.64–1.85 0.33
25–29 yrs 1.46 1.08–1.96 0.01 1.45 1.02–2.07 0.04
30–39 yrs 1.26 1.00–1.59 0.05 1.28 0.97–1.67 0.08
50–59 yrs 0.69 0.51–0.91 0.01 0.72 0.51–1.01 0.06
> 59 yrs 0.45 0.25–0.81 0.01 0.60 0.30–1.17 0.13
City of testing (ref. Cologne)
Aachen 0.77 0.36–0.91 0.02 0.89 0.53–1.50 0.66
Berlin 1.20 0.88–1.63 0.26 1.10 0.76–1.60 0.60
Bochum 0.58 0.39–0.85 0 0.72 0.45–1.13 0.16
Dortmund 0.77 0.46–1.28 0.31 1.50 0.82–2.74 0.19
Dresden 1 0.61–1.62 0.99 1.84 1.03–3.29 0.04
Munich 1.19 0.82–1.73 0.94 1.37 0.89–2.11 0.15
Nurnberg 1.56 0.73–3.32 0.25 1.71 0.68–4.30 0.25
Stuttgart 0.99 0.66–1.49 0.96 1.24 0.77–1.98 0.38
Sexual behaviour during the last 6 months
Number of male sex partners (ref. 0–5)
> 5 2.12 1.74–2.58 0.00 1.56 1.25–1.96 0.00
Sex without condom (ref. no)
yes 2.70 2.13–3.42 0.00 2.09 1.58–2.76 0.00
Use of party drugs (ref. no)
yes 2.68 2.02–3.57 0.00 1.62 1.30–2.01 0.00
* p < 0.01 for overall multivariable logistic regression model
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In contrast to previous studies, we found no difference
in STI prevalence between HIV+ and HIV- MSM [13,
14] on a descriptive level. Compared to other studies,
this was more due to a comparably higher STI preva-
lence in HIV- MSM than to a lowered prevalence in
HIV+, resulting from a very high prevalence in PrEP
using HIV- MSM. Accordingly, HIV+ MSM had a
higher risk for STI compared to HIV- non-PrEP users in
the respective multivariable model. The very low risk of
HIV transmission while having a successfully supressed
HIV infection could lead to a higher sexual risk behav-
iour and therewith a higher prevalence of STI. Anyway,
we did not find such difference comparing the overall
STI prevalence between HIV+ MSM having HIV viral
load below or above the detection limit but this may be
due to the small proportion of HIV+ MSM with viral
load above the detection limit (15.8%).
Besides PrEP use and HIV-status, we also identified
other relevant risk factors for being tested positive for an
STI. Those were behavioral factors and included report-
ing condomless sex, having had more than five male sex
partners and using party drugs, all within the last 6
months. These risk factors were also found in several
other studies [3, 6, 7, 14]. Our study complements the
results of a recent meta-analysis and other current
cross-sectional studies that showed an association be-
tween PrEP use and STI diagnosis [30], and reported
PrEP use as important risk factor for STI diagnosis [27,
40, 65]. A large longitudinal study from Australia could
even show increasing STI incidences after initiation of
PrEP [29]. A higher STI testing frequency after com-
mencing PrEP might be a confounder for higher STI
prevalences in PrEP users, but the respective study ad-
justed for STI testing frequency and recent a study from
the US showed that an increase of STI prevalence in
PrEP using MSM was independent from a concurrent
increase of STI testing in this group [66]. Despite the
concerns about rising STI incidence due to PrEP, the
clear association between PrEP use and STI diagnosis in
our study also shows that PrEP reaches the right persons
having a demand for this HIV-preventional measure.
Against this background, regular STI testing of
PrEP users is an important measure to detect STI, to
minimise the risk of sequelae on the individual level,
and to eradicate relevant transmission reservoirs on
the Public Health level. With the recently introduced
cost coverage of PrEP and accompanying STI tests by
the compulsory health insurance in Germany, the
number of PrEP users might increase probably and
therewith the number of STI diagnoses. The predic-
tion by Jenness et al. [32], that the incidence of STI
in PrEP users will decrease due to effective screening
and treatment measures, cannot be answered for
Germany currently. Monitoring the STI epidemiology
in the context of PrEP use further will therefore be of
special importance.
As our study design was cross sectional, we were not
able to analyse if MSM using PrEP showed higher sexual
risk behaviour due to their PrEP use, or if they decided
to use PrEP due to their sexual risk behaviour as a risk
minimisation strategy. However, considering the sexual
risk profile of PrEP users in our study, the results
showed clearly that PrEP reached the right persons
showing a demand for PrEP due to their sexual risk pro-
file. Besides this, we found high STI prevalences and
relevant sexual risk behaviour also in HIV- non-PrEP
users and HIV+ MSM. This highlights the need for ap-
propriate risk-adapted STI testing and treatment pro-
grams for all MSM. In this context, an effective medical
history regarding sexual health, risk and health seeking
behaviour is an important basis for delivering high qual-
ity and evidence based STI services to the relevant popu-
lations. To reach as many persons as possible, low-
threshold and low or free of cost preventive, diagnostic,
and treatment offers for STI for MSM should be broadly
available. Innovative testing offers including possibilities
for online communication and self-sampling should
complement existing local structures.
Clinical considerations
The screening frequency for CT, NG and syphilis in
asymptomatic MSM is discussed in various guidelines
for different groups: HIV+ MSM are recommended to
be screened annually, PrEP users and MSM with chan-
ging partners every 3–6 months. Our study suggests that
having more than 5 male sex partners in the last 6
months, having sex without using a condom, using party
drugs, and being HIV+ or using PrEP are the most im-
portant risk factors for MSM to acquire an STI. There-
fore all MSM reporting one or more of these items
should be screened every 3–6 months. In clinical prac-
tice it is a challenge to modify screening strategies ac-
cording to risk factors. Often simple algorithms (e.g. to
screen every HIV+ patient once a year) are used. A
structured questionnaire or score on basis of the risk
factors found could be used to allocate resources more
effectively.
With the introduction of PrEP and the challenge of
additional STI care, the questions of potential over- as
well as under-treatment gains high impact. It is widely
accepted that all symptomatic cases of STI should be
treated (including MG). Resistance testing to avoid AMR
in NG is important and a culture swab should be taken
before any GO treatment, but in clinical practice in only
less than 40% cultures yield successful results.
Asymptomatic STI are common in pharyngeal and
rectal infections. Oro-penile and oro-anal sex as well as
the use of saliva are relevant for the transmission of STI,
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particularly for gonorrhoeae [66, 67]. Spontaneous clear-
ance of CT and NG has been reported [67] but sexual
abstinence for a not defined time is not an option for
most clients. Even though they can be self-limiting,
ECDC and WHO recommend treatment of all asymp-
tomatic pharyngeal NG infections due to their high po-
tential of generating AMR in this localisation through
genetic exchange with commensal pathogens. Against
this background, all detected infections with NG, but
also CT should be treated and a test of cure should be
performed to avoid hidden transmission reservoirs.
MG screening and treatment of asymptomatic MSM is
highly debated not only due to reported genotypic resist-
ance to the standard treatment with azithromycin of up
to 80%, but also because of the partly high prevalence of
MG and the possible damage of repeated antibiotic
treatment on the microbiome (Read et al., 2019). The
collateral damage to resistomes [68–70] is already done
and cannot be reduced by ignoring wide spread of resist-
ant MG infections.
In Germany testing for MG macrolide resistance is not
yet a standard that is reimbursed by compulsory health
insurance and the best treatment of azithromycin resist-
ant strains is also not clear. Therapy guidelines recom-
mend the alternative use of Moxifloxacin [71], but using
gyrase inhibitors is limited by side effects, and resistance
is increasingly being reported in Germany as well [72].
However, resistance testing for quinolones is not widely
available yet. On the other hand many cases with macro-
lide resistant mutations can still be treated with higher
azithromycin doses or consecutive therapy of doxycyc-
line and azithromycin [71]. Assumption of costs for pris-
tinamycin is not assured in Germany, because it is only
available from international pharmacies.
MG resistance against azithromycin is more common
in MSM than in heterosexual men [73]. This is probably
due to the more frequent exposure of asymptomatic
mycoplasma infections to azithromycin when treating
CT or GO: 12% of participants tested STI positive in our
study had a concurrent infection of MG with CT, NG,
or both. Consequently, a test for MG should be consid-
ered before treatment of CT or GO to identify coinfec-
tions and avoid ineffective MG co-treatment and
undetected MG resistance. In this context, current tech-
nical developments in terms of MG resistance testing at
the clinical site could be of importance.
Generally, the STI panel of currently available com-
mercial multiplex test kits is not based on clinical useful-
ness and include too many facultative pathogens (e.g.
ureaplasma) or pathogens with no clinical implication
(e.g. mycoplasma hominis, cytomegalovirus). In case of
using these kits a good communication of the relevance
of positive test results for the specific pathogens is im-
portant. Not reporting clinically irrelevant positive
results is not only a legal issue, it is also a confession of
failure of education of medical personnel and clients.
New multiplex tests should be developed, that cover
only pathogens in clinically relevant combinations.
Partner notification is an important tool to interrupt
infection chains. In groups with many changing partners
and good communication this can lead to a high fre-
quency of prophylactic antibiotic use if notified partners
are treated immediately before getting their specific test
result, as recommended for infection with CT and NG.
Further studies have to show, if this practice of partner
treatment before testing should also be applied to PrEP
users. The context of counselling and preparing eligible
persons for PrEP is an excellent chance to screen for
STI and to sensitize for the transmission risks and con-
sequences of antibiotic treatment.
Limitations
Our study has several limitations. We recruited a con-
venience sample of MSM, so the results cannot be gen-
eralized to all MSM living in Germany. The large
proportion of higher educated among HIV-negative par-
ticipants compared to HIV-positive indicates that we ex-
perienced a selection bias. By recruiting participants
through infectiologically specialised practices, we might
have reached a more general sample of HIV-positive
MSM. They are attending these type of practice more
frequently due to their underlying chronic disease, while
HIV-negative MSM might visit these practices more
often if being better informed about this specialised ser-
vices, despite they often act as general practitioners for
MSM.
Nevertheless, as we recruited nationwide a large sam-
ple of MSM through a comprehensive network of MSM
friendly practices with infectiological focus and also
serving as general practitioners for MSM, we consider
that we could draw an epidemiological picture of a rele-
vant part of the MSM community in Germany.
By recruiting MSM via medical practices, a recruit-
ment bias towards MSM with higher probability of hav-
ing a STI could be probable. As only 32% of study
participants tested positive for any STI reported also
STI-related symptoms in the previous 4 weeks, the study
approach to reach a more general MSM population
seemed to be successful. By asking detailed questions on
sexual behavior, a reporting bias could occur. We do not
consider this as very probable, as intimate questions
such as on sexual risk behaviour and drug use were an-
swered thoroughly by the participants and specific an-
swers were not avoided. At last, a cluster effect could
influence the analyses occurring due to specific patient
populations of single study sites e.g. patients with com-
parably high sexual risk profile. This could possibly lead
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to over- or underestimation of the STI prevalence, but
the multivariable model was adjusted for that.
Conclusions
In our study, we found a high STI prevalence in MSM
in Germany; the prevalence of MG was especially high.
STI were mainly asymptomatic, and with urogenital
screening we would have only found 27.7% of all diag-
nosed STI. HIV/PrEP-status, having more than 5 sex
partners, having condomless anal intercourse (insertive
and/or receptive) and the use of party drugs were inde-
pendent risk factors for STI diagnosis.
Risk adapted, comprehensive, multi-localisation and
highly frequent STI testing for MSM using PrEP and be-
yond should be available, assuring testing options with
low threshold and free of cost. This seems to be essential
to facilitate early treatment and reduce further spread.
Counselling of PrEP users should address regular STI
testing and the risk of using party drugs. Antibiotic
stewardship is important to avoid antibiotic resistance in
frequently infected and co-infected patients.
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